
Eli Lilly and Company, Novo Nordisk A/S, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are equity shares of companies that research, develop, manufacture, and sell prescription drugs, biologics, and vaccines. For investors, they tend to carry high R&D and regulatory risk and are driven by clinical trial results, approvals and patent timelines, which can produce significant upside or volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Read Our Latest Research Report on NVO
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read Our Latest Research Report on PFE
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in December 2025
- The Toro Company: A Baby Bull Market Is Gaining Traction
- Netflix Is Out of Favor—and That’s Why It’s Getting Interesting
- Gold and Silver Exploded—Now Copper May Be the Next Big Trade
- Fresh Air, Fresh Highs: 3 Premium Outdoor Brands with 2026 Tailwinds
- MarketBeat Week in Review – 12/22 – 12/26
